Related Experiment Video
Updated: Mar 19, 2026

Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
SAHA-induced loss of tumor suppressor Pten gene promotes thyroid carcinogenesis in a mouse model
Xuguang Zhu1, Dong Wook Kim1, Li Zhao1
1Laboratory of Molecular BiologyCenter for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland, USA.
Abstract:
Thyroid cancer is on the rise. Novel approaches are needed to improve the outcome of patients with recurrent and advanced metastatic thyroid cancers. FDA approval of suberoylanilide hydroxamic acid (SAHA; vorinostat), an inhibitor of histone deacetylase, for the treatment of hematological malignancies led to the clinical trials of vorinostat for advanced thyroid cancer. However, patients were resistant to vorinostat treatment. To understand the molecular basis of resistance, we tested the efficacy of SAHA in two mouse models of metastatic follicular thyroid cancer: Thrb(PV/PV) and Thrb(PV/PV)Pten(+/-) mice. In both, thyroid cancer is driven by overactivation of PI3K-AKT signaling. However, the latter exhibit more aggressive cancer progression due to haplodeficiency of the tumor suppressor, the Pten gene. SAHA had no effects on thyroid cancer progression in Thrb(PV/PV) mice, indicative of resistance to SAHA. Unexpectedly, thyroid cancer progressed in SAHA-treated Thrb(PV/PV)Pten(+/-) mice with accelerated occurrence of vascular invasion, anaplastic foci, and lung metastasis. Molecular analyses showed further activated PI3K-AKT in thyroid tumors of SAHA-treated Thrb(PV/PV)Pten(+/-) mice, resulting in the activated effectors, p-Rb, CDK6, p21(Cip1), p-cSrc, ezrin, and matrix metalloproteinases, to increase proliferation and invasion of tumor cells. Single-molecule DNA analysis indicated that the wild-type allele of the Pten gene was progressively lost, whereas carcinogenesis progressed in SAHA-treated Thrb(PV/PV)Pten(+/-) mice. Thus, this study has uncovered a novel mechanism by which SAHA-induced loss of the tumor suppressor Pten gene to promote thyroid cancer progression. Effectors downstream of the Pten loss-induced signaling may be potential targets to overcome resistance of thyroid cancer to SAHA.
Insights
Histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) unexpectedly accelerated thyroid cancer progression in mice by inducing loss of the Pten tumor suppressor gene. This finding reveals a novel resistance mechanism and potential therapeutic targets for advanced thyroid cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Genetics
Background:
- Thyroid cancer incidence is increasing, necessitating new treatments for advanced and recurrent disease.
- Suberoylanilide hydroxamic acid (SAHA; vorinostat), a histone deacetylase inhibitor, showed limited efficacy in clinical trials for advanced thyroid cancer due to patient resistance.
- PI3K-AKT signaling pathway overactivation drives thyroid cancer, particularly in models with Pten tumor suppressor gene alterations.
Purpose of the Study:
- To investigate the molecular mechanisms underlying resistance to SAHA in metastatic thyroid cancer.
- To evaluate the efficacy of SAHA in mouse models of metastatic follicular thyroid cancer with varying Pten gene status.
- To identify potential therapeutic targets to overcome SAHA resistance in thyroid cancer.
Main Methods:
- Utilized two mouse models of metastatic follicular thyroid cancer: Thrb(PV/PV) and Thrb(PV/PV)Pten(+/-).
- Administered SAHA to mice and monitored tumor progression, metastasis, and molecular alterations.
- Performed molecular analyses including PI3K-AKT signaling pathway assessment, cell proliferation, invasion markers, and single-molecule DNA analysis for Pten gene status.
Main Results:
- SAHA demonstrated no effect on thyroid cancer progression in Thrb(PV/PV) mice, confirming resistance.
- In SAHA-treated Thrb(PV/PV)Pten(+/-) mice, thyroid cancer progression was unexpectedly accelerated, with increased vascular invasion, anaplastic foci, and lung metastasis.
- SAHA treatment led to further PI3K-AKT activation and increased expression of proliferation and invasion effectors (p-Rb, CDK6, p21(Cip1), p-cSrc, ezrin, MMPs) in Thrb(PV/PV)Pten(+/-) mice.
- Progressive loss of the wild-type Pten allele was observed in SAHA-treated Thrb(PV/PV)Pten(+/-) mice, correlating with enhanced carcinogenesis.
Conclusions:
- SAHA treatment can induce loss of the Pten tumor suppressor gene, promoting thyroid cancer progression and metastasis.
- This study uncovers a novel mechanism of SAHA resistance in thyroid cancer driven by Pten gene loss.
- Targeting downstream effectors of Pten loss-induced signaling may offer strategies to overcome SAHA resistance in advanced thyroid cancer.
More Related Videos
Related Concept Videos
Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
Abnormal Proliferation
Mouse Models of Cancer Study
The development of transgenic, knockout, and knock-in mice has led to an exponential increase in their use as model organisms in research,...
![Chemical-Induced Skin Carcinogenesis Model Using Dimethylbenz[a]Anthracene and 12-O-Tetradecanoyl Phorbol-13-Acetate DMBA-TPA](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F60445.jpg&w=3840&q=50)
